1 citations
,
May 2017 in “InTech eBooks” This review summarizes current treatments for recalcitrant alopecia areata and recent therapeutic developments targeting specific immunological pathways, reporting no new clinical results.
1 citations
,
October 2016 in “Iranian journal of psychiatry and behavioral sciences” This study presents two case reports where patients experienced hair loss during treatment with the SSRI sertraline, highlighting this rare but potential side effect.
1 citations
,
October 2025 in “International Journal of Molecular Sciences” This narrative review highlights the potential of naturally occurring compounds to target specific molecular pathways and overcome resistance in advanced and recurrent papillary thyroid cancer, offering new therapeutic possibilities beyond traditional treatments like surgery and lifelong hormone replacement.
1 citations
,
July 2025 in “Frontiers in Pharmacology” This review summarizes how foods with both medicinal and nutritional properties are being examined for their potential role in addressing post-acute COVID-19 syndrome, but it reports no new clinical results.
1 citations
,
August 2024 in “Polymers” This study observed that dissolving microneedles made from PVP-K90 and HPMC E50, incorporating Oryza sativa L. extract complex, showed enhanced transfollicular skin penetration and maintained safety for keratinocytes, with the P25H5 formulation demonstrating faster dissolution and greater effectiveness.
1 citations
,
January 2024 in “Journal of the American Pharmacists Association” In this study of transgender and gender-diverse adults, the researchers observed that one-third of those on psychotropic medications within two years of starting hormone therapy experienced psychotropic polypharmacy, with a significantly higher likelihood of potential drug-hormone interactions in this group.
July 2026 in “Biomimetics” This review discusses recent advancements in bone tissue engineering, emphasizing a shift from passive to smart responsive antibacterial strategies to prevent implant-associated infections, and highlights AI's role in optimizing bone scaffold design for personalized, infection-free implants.
January 2026 in “Pharmaceutical Medicine” January 2026 in “Ethnobiology”
December 2025 in “International Journal of Innovative Technologies in Social Science” This review examines how lifestyle factors like diet, smoking, and stress may influence alopecia areata, but concludes that current evidence is inconsistent and largely observational, urging further research.
September 2025 in “Stem Cell Research & Therapy” This study found that TAZ promotes adipogenesis in goat adipose-derived mesenchymal stem cells by enhancing PI3K/AKT pathway activity, with overexpression boosting adipocyte formation and knockdown inhibiting it.
This review found that 5α-reductase inhibitors (such as finasteride and dutasteride) effectively reduce prostate size and stabilize hair loss but are associated with sexual dysfunction; they remain essential treatments for BPH and androgenic alopecia, requiring tailored risk-benefit assessments.
This review analyzed clinical trials and guidelines on 5-α-reductase inhibitors (5-ARIs) and found these drugs significantly improve urinary symptoms in BPH and stabilize hair loss in androgenic alopecia, but may cause sexual dysfunction and gynecomastia.
July 2025 in “Saudi Journal of Medicine and Public Health” In this review, 5α-reductase inhibitors like finasteride and dutasteride were found to significantly reduce prostate volume and stabilize hair loss, but they also carry risks of sexual dysfunction, necessitating careful patient evaluation and monitoring.
March 2025 in “Biomedical & Pharmacology Journal” This observational study found that while 96.6% of patients using valproic acid showed the expected clinical response, over half experienced adverse reactions like weight gain, hair loss, and hepatotoxicity, highlighting the need for personalized treatment approaches to minimize these side effects.
November 2024 in “Fermentation” In this study, researchers found that fermented ginsenoside from kimchi-derived bacteria enhanced hair growth in a mouse model and increased hair cell proliferation by 25% in vitro, suggesting potential as a therapeutic candidate for promoting hair growth.
November 2024 in “Journal of Functional Foods” In this study, APC collagen peptides were observed to enhance hair elasticity and gloss in human hair follicles by increasing amino acid and lipid component levels, suggesting their potential benefits for improving hair qualities.
May 2024 in “International Journal of Nanomedicine” This review examined the diverse therapeutic potentials of cannabinoids, highlighting their applications in pain, neurological, and cancer treatments, and emphasized the benefits of biodegradable polymers in improving drug delivery; however, further clinical trials are needed to fully explore these potentials.
April 2024 in “Human genomics” This study identified MPB susceptibility genes and potential drug candidates that may help uncover molecular mechanisms and address male-pattern baldness.
March 2024 in “Journal of functional biomaterials” This study demonstrated that a strain of lactic acid bacteria from kimchi, identified as Pediococcus inopinatus, showed antibacterial activity against certain oral pathogens and effectively bleached stained artificial teeth and inhibited biofilm formation, offering potential for addressing teeth discoloration and halitosis.
February 2024 in “Archiv EuroMedica” This review suggests that annurca apple extract, rich in polyphenols, may be a promising alternative for treating baldness, though further research is needed to clearly assess its effectiveness compared to existing treatments.
July 2023 in “Ageing & Longevity” This review discusses two approaches to address aging: a tactical method to delay and slow age-related issues, and a strategic method aiming to eliminate aging altogether by targeting its root cause.
January 2023 in “Journal of The American Society of Nephrology” This article discusses the potential benefits and challenges of metatrials as a new clinical trial methodology during COVID-19 and reflects on its application in nephrology, but reports no new results.
October 2016 in “Iranian journal of psychiatry and behavioral sciences” This case study reports instances of hair loss in two patients taking sertraline, suggesting that even low doses of SSRIs might cause this rare side effect, which could impact treatment adherence.
June 2026 in “Frontiers in Medicine” This study conducted a large-scale comparison using FAERS data to assess the post-marketing safety profiles of spironolactone, eplerenone, and finerenone, finding unique adverse event patterns for each drug and highlighting the need for personalized safety monitoring and further investigation in other pharmacovigilance databases.
June 2026 in “International Journal of Molecular Sciences” This review synthesizes current evidence on the Warburg effect in anaplastic thyroid carcinoma and discusses potential therapeutic targets, but reports no new clinical results.
March 2026 in “The Aging Male” This retrospective pharmacovigilance study reviewed adverse event reports from 2004 to 2025 for drugs treating benign prostatic hyperplasia, identifying distinct safety signals for α1-blockers, 5ARIs, and PDE5I, including some potential new adverse events that require further investigation.
September 2025 in “Clinical Cosmetic and Investigational Dermatology” This study in Jordan found that topical corticosteroid use is common and often involves creams obtained without prescriptions, with only 61.3% of users aware of potential side effects, highlighting a need for better public education and regulation to prevent misuse.
June 2025 in “Frontiers in Neurology” This study found a significant association between finasteride use and increased risk of memory impairment, highlighting the need for risk communication and routine cognitive monitoring for long-term users.
This study utilized the USFDA AERS to identify significant associations between various medications—such as anti-osteoporotic drugs and phenytoin—and gingival disorders, noting emergent signals with finasteride, COVID-19 vaccine, and levothyroxine, suggesting a need for awareness of oral side effects.